Growth of Hyperactive Children on Maintenance Regimen of Methylphenidate

Mattes, Jeffrey A.; Gittelman, Rachel

doi:10.1001/archpsyc.1983.01790030087011

Cited by 130 publications

(47 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We did not observe any significant differences in height SDS and weight SDS in the patients during the study period. The literature is conflicting in this respect, reporting height deficits in children treated with methylphenidate in some [9,10,11,12,13,14,15, 25] but not all studies [16,17,18,19,20,21,22,23,24]. The reasons for the inconsistent results are methodological problems mentioned in the Introduction.…”

Section: Discussionmentioning

confidence: 99%

“…However, it is not well characterized whether growth retardation is due to an intrinsic abnormality or secondary to psychostimulant medications used in treatment of ADHD. Some of the earlier studies suggest that growth suppression and poor weight gain are related to methylphenidate treatment [9,10,11,12,13,14,15], however this effect was not observed in all studies [16,17,18,19,20]. Recent studies also gave conflicting results in this matter [23,24,25,26].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Height, Weight, IGF-I, IGFBP-3 and Thyroid Functions in Prepubertal Children with Attention Deficit Hyperactivity Disorder: Effect of Methylphenidate Treatment

Bereket¹,

Turan²,

Karaman³

et al. 2005

Horm Res Paediatr

View full text Add to dashboard Cite

Objective: To investigate if there are any disease-related or methylphenidate-induced aberrations in growth parameters, growth hormone insulin-like growth factor (IGF)-I, IGFBP-3 axis and the thyroid function tests in children with attention deficit hyperactivity disorder (ADHD). Methods: Newly diagnosed and untreated prepubertal children with ADHD were longitudinally followed before and approximately every 4 months after methylphenidate treatment for up to 16 months. Height SDS, weight SDS, BMI SDS, serum GH, IGF-I, IGFBP-3, T₄, free T₄, T₃, and TSH were measured at each visit. Results: All of the examined parameters were within normal limits for age before treatment. Methylphenidate treatment did not significantly affect SDS of height, weight, BMI, IGF-I and IGFBP-3 in the long run. Serum T₄ and free T₄ levels showed modest reductions within normal limits in a time-dependent manner. Conclusions: Prepubertal children with ADHD had normal height, weight, BMI, serum IGF-I and IGFBP-3 and thyroid functions. Methylphenidate treatment had no sustained effects on growth parameters, IGF-I and IGFBP-3 during the follow-up period of this study. However, it caused a mild decrease in total and free T₄ which may warrant further monitoring.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Height, Weight, IGF-I, IGFBP-3 and Thyroid Functions in Prepubertal Children with Attention Deficit Hyperactivity Disorder: Effect of Methylphenidate Treatment

Bereket¹,

Turan²,

Karaman³

et al. 2005

Horm Res Paediatr

View full text Add to dashboard Cite

show abstract

“…Since MPH is reported to be equally effective as amphetamine in the management of ADD/H [2,24] while at the same time producing milder side effects, MPH has become the most commonly used stimulant in the treatment of ADD/H [17,20]. Although the vast majority of controlled studies show the stimulants to be effective in treating ADD/H.…”

Section: Introductionmentioning

confidence: 99%

Methylphenidate and Growth: Demonstration of a Growth Impairment and a Growth-Rebound Phenomenon

Pizzi¹,

Rode²,

Barnhart³

1986

Dev Pharmacol Ther

View full text Add to dashboard Cite

Methylphenidate (MPH), the drug of choice in the treatment of attention deficit disorder with hyperactivity (ADD/H), has been shown to reduce the body stature of some patients. The present study was undertaken to determine if MPH suppresses growth in rats, and whether the clinical observation of a growth rebound phenomenon could be experimentally demonstrated. Our results demonstrate that neonatal rats treated with MPH show a reduction in femur length and a reduction in thyroid, pituitary, testis, adrenal gland, and brain weights immediately following drug cessation. However, a growth- rebound phenomenon occurs such that there are no differences between treated and control groups within 30 days of the last drug exposure. These data, along with those from the clinical literature, suggest that growth impairment is most likely a result of the acute effects of the drug. Further, these data suggest that when administered at therapeutic doses which avoid significant weight loss in the patient. MPH is not likely to cause growth impairment in children.

show abstract

“…A 30-year experience with daily dextroamphetamine has shown that side effects are minimal and disappear within a week or two [74]. In childhood ADHD, methylphenidate may decrease weight percentiles after 1 year and height percentiles after 2 years [84]. Dosage is significantly associated with the decrease in height and weight percentiles.…”

Section: Side Effects and Toxicitymentioning

confidence: 99%

Psychostimulants in supportive care

Homsi

Walsh

Nelson

2000

Supportive Care in Cancer

View full text Add to dashboard Cite

Psychostimulant medications have been used clinically and investigated in psychiatric populations, the medically ill, cancer patients and healthy people. This article discusses the pharmacology of dextroamphetamine, methylphenidate, pemoline (and other psychostimulants such as caffeine and ephedrine), their use in general medicine and cancer care, side effects, and abuse potential. Therapeutic use in children is addressed only insofar as it illustrates facets of their use in adults.

show abstract

Growth of Hyperactive Children on Maintenance Regimen of Methylphenidate

Cited by 130 publications

References 14 publications

Height, Weight, IGF-I, IGFBP-3 and Thyroid Functions in Prepubertal Children with Attention Deficit Hyperactivity Disorder: Effect of Methylphenidate Treatment

Height, Weight, IGF-I, IGFBP-3 and Thyroid Functions in Prepubertal Children with Attention Deficit Hyperactivity Disorder: Effect of Methylphenidate Treatment

Methylphenidate and Growth: Demonstration of a Growth Impairment and a Growth-Rebound Phenomenon

Psychostimulants in supportive care

Contact Info

Product

Resources

About